
pm et
summari global leader develop sale anim vaccin medicin diagnost
livestock produc veterinarian
price-to-earnings oper ep
risk assess reflect compani lead
posit global anim heath space
possess strong product divers geograph reach
well strong growth potenti see global
pet ownership rate middl class expand less
develop market also less expos
research develop patent reimburs risk
face tradit human pharmaceut firm
posit factor somewhat mitig potenti
restrict antibiot food-produc anim
 europ
feb ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
past perform indic futur perform reli upon
analysi prepar equiti analyst
pm stock trade
ytd sale yoy led
robust growth companion segment
total revenu sale yoy
growth companion sale aid
acquisit ca-bas abaxi juli
maker diagnost instrument veterinari
care well robust growth intern
deceler yoy high
singl digit demand
weaken cattl product
excel growth opportun pet
ownership rate increas rise median
incom view think intern
market expand middl class
china gener long-term robust
demand growth compani ytd
intern companion revenu
yoy current compris
total sale
also invest heavili new product
product capabl ytd
 capital-expenditure
yoy respect think invest
yield strong sale growth margin
improv opportun
think durabl leadership posit
anim health product view
share fulli valu current premium
long-term averag price-to-earnings multipl
grow strong volum price increas
think continu strong
posit rais price futur year
especi true companion segment
think end-custom pet owner
especi like accept routin price
increas rather withhold medic
benefit pet
expect continu robust sale earn
growth see size
larg invest capital-expenditure
maintain competit advantag risk
view includ greater regulatori scrutini
use antibiot livestock increas
competit over-the-counter anim health product
declin pet ownership rate
target ep
estim long-term averag
forward price-to-earnings expect recent
intern expans companion
segment fuel above-averag growth
result larg capital-expenditure invest
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview zoeti global leader discoveri develop manufactur
market anim health medicin vaccin focu livestock companion
anim compani market divers rang product livestock speci cattl beef
dairi swine poultri sheep fish companion anim speci dog cat hors chief
product categori anti-infect vaccin parasiticid medic feed addit
pharmaceut product also offer diagnost devic anim health product
servic accord anim health market estim billion
formerli anim health divis zoeti becam separ entiti stock
complet initi public offer million zoeti class share
interest earli februari subsequ late june divest remain
interest zoeti holder exchang million class share
compani directli market product countri product sold anoth nation
non-direct channel sale account
brazil largest intern market sale account total
sale
livestock farm anim product mainli cattl swine account total sale
compris item cattl swine poultri fish sheep select
livestock product includ ceftiofur draxxin antibiot cattl swine sheep bovishield
improvac respisur rispov vaccin cattl swine cydectin dectomax parasiticid
cattl sheep long-term macro driver livestock product includ growth global
popul rise standard live rise demand improv nutrit particularli anim protein
product companion pet primarili dog cat repres sale princip brand
includ clavamox covinia terramycin anti-infect vanguard vaccin revolution/stronghold
parasiticid growth busi driven econom develop relat increas
treatment companion anim advanc anim health medicin vaccin
corpor strategi compani may pursu acquisit technolog licens arrang
strateg allianc divestitur busi part overal strategi drive growth
leverag road global footprint zoeti strive provid custom innov product
servic also place great emphasi spawn extens diversifi product
portfolio line latter strategi compani pursu develop new vaccin
emerg infecti diseas anim
competit landscap zoeti largest player estim billion global anim health
market market share key competitor includ merck anim health merial
anim health divis sanofi elanco anim health divis bayer anim health
financi trend zoeti form januari spin-off inc sale
increas billion billion sale rose billion
sale fell modestli billion sale rose billion sale rose
billion adjust ep improv
ep expect market grow mid-single-digit
rang long term expect grow sale line faster market
base combin industri lead resourc suppli believ keep
oper expens growth within rang inflat rate believ grow ep low
doubl digit next sever year
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
fairli valu
bullish sinc novemb technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
outlook pharmaceut sub-industri
next month posit view
reflect strong novel drug approv activ
see fda posit
brand drug maker repres
lion share sub-industri market
cap view temper expect
continu pressur gener drug price
neg gener drug maker lower
growth overal prescript volum
far year-over-year increas
brand drug price per prescript
around accord iqvia estim
aid strong novel drug approv activ
fda particularli weak year
novel drug approv number
rebound pace
strong growth well approv alreadi
made octob expect strong
pace novel drug approv brand drug
price inflat continu next year
aid estim approxim
year-over-year growth brand pharma
spend year end june
side coin
outlook gener drug price mostli
neg growth gener drug price
averag around neg far
dont expect major near-term
revers trend toward posit price
growth think deflationari trend
mostli driven robust gener drug
approv activ fda custom
consolid rather polit
total gener drug approv hit record
grow year-over-year
increas competit exist gener
view bring price pace
gener approv seem moder
howev approv
august versu
expect moder
deflat howev bring full-on
gener inflat due view
purchas joint ventur
three major drug distributor three largest
 retail pharmaci limit gener maker
abil rais drug price environ
joint ventur account
gener sale estim includ
cardin
walgreen
beyond drug price think prescript
volum growth fall
next year strong gain health insur
growth think
gain harder come
next year unemploy near
all-tim low remov tailwind
prescript volum growth go forward
view assum slower growth
number peopl enrol health insur
plan gener mean slower growth
use total enrol figur eight
largest health insur proxi
estim number individu
famili health insur grew
growth slow
coincid roughli growth
prescript volum far versu
accord iqvia estim
expect slow next year
increas versu rise
composit index year-to-d
octob
rise composit index
base index
five-year market price perform
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
livestock product sale rose companion product
livestock product aid new product encourag
solid sale growth see trend continu aid new
approv market product simparica /jeffrey loo cfa
rais target above-p forward
ep estim faster growth ep vs
ahead estim rais ep estim
sale rose driven robust companion anim
product sale rise livestock sale rebound recent soft
quarter rose strong demand fish poultri product partial
off-set soft cattl swine demand growth also geograph
broad-bas rise oversea /jeffrey loo cfa
keep target peer forward
ep faster growth reimburs issu ep
vs estim higher expect cost
partli cost relat new direct-to-consum campaign lower
ep estim sale rose driven companion anim
busi sale livestock product rose sale rose
 oversea believ divers portfolio geograph
presenc continu provid stabil /jeffrey loo cfa
analyst research note compani news
keep target ep estim
long-term averag forward price-to-earnings expect recent acquisit
expans companion anim segment fuel above-averag growth
ep vs ahead consensu maintain ep
estim lower start sale rose
yoy led robust growth companion segment total revenue
grew sale yoy aid acquisit
ca-bas abaxi juli well robust growth intern companion
sale believ intern companion sale remain excel growth
opportun companion lead growth livestock
segment tot revenue livestock sale growth deceler yoy
high single-digit weaker cattl demand like
market posit growth outlook high valuat keep us neutral
rais target price above-p
forward ep estim above-p growth ep
vs ahead estim rais ep estim
ep estim sale rose
believ gain market share strong demand new
parasiticid vaccin dermatolog product sale rose
companion anim product sale livestock product sale
sale rose companion anim product livestock
modest soft sale cattl product partial off-set strong sale
poultri swine product complet acquisit abaxi
develop veterinari diagnost instrument juli see veterinari
diagnost one fastest grow area anim health industri
et cfra keep hold opinion share zoeti inc
agre acquir abaxi abax nr share cash
total abax lead provid veterinari diagnost
forecast fy sale oper margin
consensu ep although view veterinari diagnost fast
grow segment within anim health forecast compound annual industri
sale growth next three year believ
pay sizeabl premium fy ep particularli sinc abax
oper margin well oper margin
expect deal subject approv close
year-end expect materi impact result
see deal accret earn believ larger global
presenc benefit abax oper deriv sale
rais target price above-p
ep estim ep vs
ahead estim aid lower tax rate compar
year ago sale includ fx benefit grew sale
grew companion anim product livestock product
aid improv growth swine busi sale
fx benefit rose companion product oper basi
livestock product oper basi gross margin improv
basi point mainli improv intern market see growth
driven new product launch particularli dermatolog product
rais target peer
ep estim set ep vs
ahead view sale rose growth
forecast sale rose companion anim product
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
